# Mylan Institutional, a Viatris Company: Etomidate Injection shortage reverified (available from this maker)

**Score:** 35/100

| Field | Value |
|---|---|
| Manufacturer | Mylan Institutional, a Viatris Company |
| Drug | Etomidate Injection |
| Dosage form | Injection |
| Therapeutic category | Anesthesia |
| Status | Current |
| Stage | Shortage reverified (still listed) |
| Availability | Available |
| Reason | Demand increase for the drug |
| Presentations affected | 2 |
| Package NDCs | 67457-902-10, 67457-903-20 |
| Manufacturer supply note | Estimated recovery: November 2026 |
| First posted | 2022-10-05 |
| Updated | 2026-10-19 |

## Why this score
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.